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Research
Pulse pressure (PP), the pulsatile compo-
nent of blood pressure, is a surrogate marker 
of arterial stiffness and compliance. With 
increasing age, arteries stiffen because of loss 
of elasticity, calcification, and atherosclero-
sis in the vessel wall (Zieman et al. 2005). 
Increased PP has been shown in a number 
of studies to be a strong predictor of cardio-
vascular diseases, even after other risk fac-
tors were controlled for (Dart and Kingwell 
2001). The mechanisms responsible for PP 
progress remain unclear. Whole genome and 
candidate gene analyses for PP have shown a 
significant genetic influence but have failed to 
identify specific allele determinants, probably 
because of the multifactorial etiology of arte-
rial stiffness (Bielinski et al. 2005; Lacolley 
et al. 2009).
Although the relationship between lead 
exposure and increased blood pressure has 
been well established (Hu et al. 1996; Navas-
Acien et al. 2007), the impact of lead on PP 
has been studied only to a limited extent. 
Lead can accumulate in the body after expo-
sure, and the aorta is the second most lead-
laden organ next to the skeleton in humans 
(Barry and Mossman 1970; Schroeder and 
Tipton 1968). As a prooxidant metal, lead 
has been implicated in atherosclerosis, periph-
eral vascular diseases, and other adverse car-
diovascular end points (Navas-Acien et al. 
2004, 2007). In our previous report (Perlstein 
et al. 2007), cumulative community-level lead 
exposure, as measured by in vivo measure-
ments of lead in bone, was significantly asso-
ciated with increased PP. The extent to which 
lead accumulation contributes to promoting 
vascular impedance is not clearly established.
Polymorphisms in the hemochromatosis 
gene (HFE) are well known to promote life-
long excessive iron absorption and accumu-
lation and the risk of developing late-  onset 
hereditary hemochromatosis, a common 
autosomal recessive, multisystemic disease. 
Two major mutations are known in the HFE 
gene: C282Y and H63D mutations. The pro-
tein encoded for by HFE gene binds to the 
transferrin receptor and reduces its affinity for 
iron-loaded transferrin and the subsequent 
cellular uptake of iron (Feder et al. 1998). 
The H63D-mutated protein (histidine-63-
  aspartate) appears to form stable complexes 
with the transferrin receptor and lowers its 
binding affinity for transferrin that leads to 
relatively small increments of cellular iron 
content, whereas C282Y-mutated protein 
(cystein-282-tyrosine) is expressed with 
unfolded/misfolded configuration and aggre-
gates and remains in the endoplasmic reticu-
lum (Gray et al. 2009). Homozygosity for 
C282Y variant is the main susceptibility gen-
otype and is highly prevalent (50–100%) in 
hereditary hemochromatosis. Heterozygotes 
for C282Y, the homozygosity for variant 
H63D, and the compound heterozygotes of 
H63D and C282Y also succumb to hemo-
chromatosis with a lower penetrance (Burke 
et al. 2000).
HFE mutations are also associated 
with altered lead biomarker concentrations 
(Wright et al. 2004) and modification of the 
impact of cumulative lead exposure on cogni-
tion (Wang et al. 2007), QT prolongation 
(Park et al. 2009), and air particle-related 
metal transport (Park et al. 2006) in elderly 
men, suggesting that protein encoded for by 
the HFE gene may modulate lead toxicity as 
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Ba c k g r o u n d: Cumulative lead exposure is associated with a widened pulse pressure (PP; the 
  difference between systolic and diastolic blood pressure), a marker of arterial stiffness and a predictor 
of cardiovascular disease. Polymorphisms in the hemochromatosis gene (HFE) have been shown to 
modify the impact of cumulative lead exposure on measures of adult cognition and cardiac function.
oBjectives: We examined whether the HFE mutations modify the impact of lead on PP in 
 community-dwelling older men.
Me t h o d s : We examined 619 participants with a total of 1,148 observations of PP from a substudy 
of bone lead levels (a measure of cumulative exposure, measured by in vivo K-shell X-ray fluores-
cence) and health in the Normative Aging Study between 1991 and 2001. Linear mixed-effects 
regression models with random intercepts were constructed.
re s u l t s: Of the 619 subjects, 138 and 72 carried the HFE H63D and C282Y variants, respec-
tively. After adjusting for age; education; alcohol intake; smoking; daily intakes of calcium, 
sodium, and potassium; total calories; family history of hypertension; diabetes; height; heart rate; 
high-density lipoprotein (HDL); total cholesterol:HDL ratio; and waist circumference, baseline 
bone lead levels were associated with steeper increases in PP in men with at least one H63D allele 
(p-interaction = 0.03 for tibia and 0.02 for patella) compared with men with only the wild types or 
C282Y variant.
co n c l u s i o n s: The HFE H63D polymorphism, but not the C282Y mutation, appears to enhance 
susceptibility to the deleterious impact of cumulative lead on PP, possibly via prooxidative or pro-
inflammatory mechanisms.
key w o r d s : gene–environment interaction, hemochromatosis gene, H63D mutation, lead expo-
sure, pulse pressure. Environ Health Perspect 118:1261–1266 (2010).  doi:10.1289/ehp.1002251 
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well as iron uptake. These findings prompted 
us to hypothesize that the HFE gene muta-
tion would modify the effects of lead on PP. 
Furthermore, because H63D and C282Y 
are known to have different penetrance rates 
(Burke et al. 2000), there may be a primacy 
of one HFE variant allele over the other in 
modifying lead toxicity. To address these 
issues, the aims of this study were to evaluate 
potential interactions between HFE genotypes 
and bone lead and to reconcile the difference 
of allele effects on PP in a subgroup of com-
munity-dwelling older men (those who are 
healthy, have no occupational or extra envi-
ronmental risks from exposure to toxicants, 
and generally represent the population of the 
United States) from the Normative Aging 
Study (NAS).
Materials and Methods
Study population. The NAS is an ongo-
ing longitudinal study of aging initiated by 
the U.S. Veterans Administration in 1963, 
when 2,280 healthy men, mostly white and 
21–80 years of age, from the Greater Boston, 
Massachusetts, area were enrolled. All par-
ticipants in the study had no history of heart 
disease, hypertension, diabetes, cancer, pep-
tic ulcer, gout, recurrent asthma, bronchi-
tis, or sinusitis. Those with either a systolic 
blood pressure > 140 mmHg or a diastolic 
blood pressure > 90 mmHg were disqualified 
for enrollment. Between August 1991 and 
December 1995, 744 NAS participants who 
gave their informed consent were invited to 
undergo bone lead measurements. Of those 
subjects in the lead study, 632 were success-
fully genotyped for HFE gene. To evaluate 
effect modification by allele-specific HFE 
variances, men heterozygous for both C282Y 
and H63D polymorphisms (known as com-
pound heterozygote; n = 13) were excluded; 
thus, 619 participants were finally included 
in the study. Complete medical and family 
histories, physical examinations, and labora-
tory tests closest to the time point of bone 
lead measurements were defined as baseline 
measurements. Every 3–5 years, the partici-
pants were scheduled for follow-up examina-
tions. Between August 1991 and December 
2001, there were 529 follow-up examinations 
among those 619 participants; therefore, a 
total of 1,148 observations were used in the 
analysis (246, 217, and 156 subjects have one, 
two, and three observations, respectively). The 
study protocol was approved by the institu-
tional review board at each study site.
Blood pressure measurements. During 
each clinical visit, the participants came to the 
study center in the morning after abstaining 
from smoking and drinking for at least 12 hr. 
Immediately after the history review, while the 
subject remained seated, systolic blood pres-
sure and fifth-phase diastolic blood pressure 
were measured to the nearest 2 mmHg, first in 
the left arm and then in the right arm, with a 
standard mercury sphygmomanometer with a 
14-cm cuff. For this study, the means of the 
left and right arm measurements were used as 
systolic and diastolic blood pressure for each 
participant, and PP was calculated as the sys-
tolic minus the diastolic blood pressure.
Laboratory measurements. Bone lead levels 
were measured closest in time to the first visit 
using a K-shell X-ray fluorescence  instrument 
(ABIOMED, Danvers, MA) at two sites: the 
midtibial shaft and the patella, which represent 
the cortical and trabecular bone compartments 
(Hu et al. 1996; Kim et al. 1995). Multiplex 
polymerase chain reaction assays were designed 
with Sequenom SpectroDESIGNER software 
(Sequenom, Inc, San Diego, CA) by input-
ting sequence containing the single-nucleotide 
polymorphism (SNP) site and 100 bp of 
flanking sequence on either side of the SNP, as 
previously described (Park et al. 2006; Wright 
et al. 2004). For further measurement details, 
see Supplemental Material (doi:10.1289/
ehp.1002251).
Covariates. Covariates were chosen based 
on biology, potential mediating effects, and 
prior studies (Hu et al. 1996; Perlstein et al. 
2007). Information about age, race, and eth-
nicity, as well as medical and family history 
were obtained from the interview. Information 
about heart rate, body mass index (BMI) waist 
circumference, physical activities, and alcohol 
use were obtained from the physical examina-
tion and examination-associated questionnaire, 
respectively. The identity and purpose of med-
ications prescribed by the subject’s physician 
were confirmed. Dietary intake was assessed 
using a standardized food frequency ques-
tionnaire. In the present study, the nutrients 
examined, such as potassium, sodium, and 
calcium, were adjusted for total energy intake. 
Information about education and cigarette 
smoking was also obtained by questionnaire.
Statistical analysis. Statistical analysis 
was carried out using SAS (version 9.1; SAS 
Institute Inc., Cary, NC) and R version 2.7.2. 
(R Foundation for Statistical Computing, 
Vienna, Austria), and the primary outcome 
measure was PP. All probability measures cor-
responding to statistical significance are two 
tailed (α = 0.05). We used the generalized 
extreme studentized deviation many-outlier 
method (Rosner 1983) to remove extreme 
outliers among the continuous independent 
variables with a normal distribution, as in 
previous analyses. Given the high penetrance 
of two HFE variant alleles over single HFE 
variant alleles, it is possible that the magni-
tudes of effect modification among H63D 
homozygotes or C282Y homozygotes is larger 
than that among H63D heterozygotes or 
C282Y heterozygotes. However, because there 
were small sample sizes in HFE homozygote 
genotype, we were unable to test alleles dose 
responses. Instead, we classified the HFE 
genotypes into two different manners: binary 
[wild type (having only HFE wild-type alleles) 
and any HFE variant allele], and allele-
specific [wild type, and mutually exclusive 
C282Y (having one or two C282Y variant 
allele) and H63D (having one or two H63D 
variant alleles)] in this study. Compound 
heterozygotes were excluded in all analyses. 
Allele and genotype frequencies and tests 
for Hardy–Weinberg equilibrium were per-
formed. Because PP was measured repeatedly 
across time in the same individual, we fit a 
linear mixed-effects regression model with 
random intercepts using the PROC MIXED 
procedure in SAS to account for lack of inde-
pendence of observations and the subject-
specific intercept that reflects unexplained 
heterogeneity in the overall intercept (Singer 
and Willett 2003). To assess effect modifica-
tion by the different HFE alleles, we included 
a term for the lead biomarker, indicator vari-
ables for HFE genotype classification, and 
cross-product terms between lead biomarker 
and HFE genotype, along with baseline age 
(years), age squared, time elapsed from the 
baseline (years), height (centimeters), educa-
tion, alcohol intake (grams per day), smoking 
(pack-years), daily intakes of calcium, sodium, 
and potassium (milligrams), total calories 
(kilocalories per day), physical activity, diabe-
tes, family history of hypertension, heart rate, 
high-density lipoprotein (HDL, milligrams 
per deciliter), total cholesterol-to-HDL ratio, 
and waist circumference (centimeters). We 
fit additional models that further adjusted 
for hypertension, ischemic heart disease, and 
diabetes mellitus as well as medications for 
hypertension, diabetes, and hyperlipidemia. 
We initially included an interaction between 
time and bone lead marker in the mixed-ef-
fects model to capture the longitudinal asso-
ciation between bone lead and PP over time. 
We excluded the interaction term because it 
was not significant, and it is difficult to test 
effect modification by HFE genotype.
The mixed model we used is described as 
follows:
Yij = (b0 + ui) + covariates + b1C282Yi  
  + b2H63Di + b3Pbi + b4C282Yi  × Pbi 
  + b5H63Di × Pbi + eij ,  [1]
where Yij is PP in subject i at visit j, b0 is the 
overall intercept, ui is a subject-specific inter-
cept that reflects unexplained heterogeneity 
in the overall intercept, and b1,.., b5 are the 
slopes representing the estimated effects of 
C282Y HFE and H63D HFE compared with 
wild-type carriers, and the estimated effects 
of lead among wild type, C282Y HFE, and 
H63D HFE, respectively. To check whether 
the associations between PP and each lead HFE H63D gene, lead, and pulse pressure
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marker were linear, we used the general-
ized additive mixed model (GAMM) with 
bone lead marker as penalized spline, which 
allows the relation between the exposure and 
response to be more flexible and thus allows 
for possible nonlinearity of the association. 
This was implemented using the R software.
Results
Table 1 shows the genotype frequencies along 
with tibia and patella lead levels at baseline 
by HFE genotypes. Median concentrations 
of bone lead in our study population were 
19 and 26 µg/g for tibia and patella, respec-
tively. The distributions of both H63D and 
C282Y genotypes were in Hardy–Weinberg 
equilibrium (H63D: χ2 = 2.97, p = 0.09; 
C282Y: χ2 = 1.17, p = 0.36), which is con-
sistent with the previously reported preva-
lence for HFE genotypes in the NAS cohort 
(Wright et al. 2004). Because of the small 
numbers in both H63D and C282Y homozy-
gotes groups, our study population was fur-
ther merged into two categories indicating the 
presence of any H63D or C282Y allele. As a 
result, 138 (21.8%) and 72 (11.4%) men had 
at least one H63D variant allele and C282Y 
variant allele, respectively. There were no dif-
ferences in bone lead levels among HFE wild 
type, H63D, and C282Y variant carriers.
Table 2 presents baseline information of 
characteristics for the NAS men in our study 
sample (n = 619). Subjects with HFE variant 
had lower levels of HDL cholesterol and were 
more likely to have diabetes. C282Y vari-
ants had higher intake of calories and lower 
intake of calcium compared with H63D and 
wild-type subjects. Although systolic blood 
pressure and PP levels appeared higher in the 
H63D variant carriers, these measures were 
not significantly different from C282Y vari-
ant carriers or wild types. Compared with 
the men excluded (missing HFE genotype; 
n = 112), the men in our study sample were 
younger (66 vs. 70 years), had lower tibia 
and patella bone lead levels (19 vs. 22 µg/g 
and 26 vs. 32 µg/g for tibia and patella lead 
levels, respectively), and were less likely to 
have diabetes and use hypertension medica-
tions than those excluded (6.1% vs. 12.5% 
and 8.5% vs. 16.9% for diabetes prevalence 
and use of hypertension medications, respec-
tively. [See Supplemental Material, Table 1 
(doi:10.1289/ehp.1002251) for details.] As 
expected, there was an average of 2-mmHg 
increases in PP of the study participants dur-
ing the follow-up period (mean follow-up 
years = 4.9 ± 5.8).
We examined the associations of HFE 
alleles with PP independent of lead expo-
sures (data not shown). After controlling 
for the same potential confounders listed in 
“Statistical Analysis,” no HFE gene variants 
alone (either binary or allele-specific HFE 
variants) were significantly associated with 
PP. In the previous cross-sectional analysis 
(Perlstein et al. 2007), bone lead levels, not 
blood lead levels, were significantly associated 
with increased PP. In this expanded follow-up 
with a total of 1,148 observations, we did not 
find a significant interaction between time 
elapsed and tibia lead or patella lead in the 
determination of PP. Therefore, we removed 
the interaction term between time and bone 
lead from the model when we tested the 
interaction between bone lead and HFE geno-
type. Coefficients for any HFE variant effects 
on PP were not substantially changed after 
the addition of either tibia or patella lead to 
each of the PP models. In the multivariable 
regression models that included an interaction 
term between baseline bone lead levels and an 
indicator for having any HFE variant alleles, 
we found a significantly positive interaction 
for PP. Interestingly, in additional regression 
analyses including either H63D or C282Y 
separately, the observed interaction remained 
consistently significant only for H63D, 
not for C282Y. Higher tibia or patella lead 
was associated with a steeper increase in PP 
among the H63D participants compared with 
C282Y or wild-type men (p < 0.05) (Table 3). 
Among men with at least one H63D allele, 
interquartile range (IQR) increases of the lead 
Table 1. Genotype frequencies along with bone lead levels [median (interquartile range)] by HFE genotype.
Genotype No. (%)  Tibia lead (µg/g) Patella lead (µg/g)
Wild type  409 (66.1) 18 (12–27) 26 (17–37)
C282Y heterozygotes  67 (10.8) 20 (14–26) 25 (17–37)
C282Y homozygotes  5 (0.8) 34 (16–39) 34 (22–58)
H63D heterozygotes  122 (19.7) 19 (14–27) 27 (19–37)
H63D homozygotes  16 (2.6) 17.5 (13.5–21.5) 26.5 (18.5–37)
C282Y variantsa 72 (11.6) 20 (14–27) 25 (17–37)
H63D variantsb 138 (22.3) 19 (14–26) 27 (19–37)
Any HFE variantsc 210 (33.9) 19 (14–27) 26 (18–37)
All subjects 619 (100) 19 (13–27) 26 (18–37)
aPresence of any C282Y variant. bPresence of any H63D variant. cPresence of any C282Y or H63D variant.
Table 2. Characteristics of men at the baseline lead measurements by HFE genotype.
Characteristic
Wild type  
(n = 409)
C282Y  
(n = 72)
H63D  
(n = 138) p-Value
Continuous variables (mean ± SD)
Age  66.4 ± 7.0 66.9 ± 7.1 66.9 ± 6.8 0.78
BMI  27.8 ± 3.6 27.8 ± 3.6 27.6 ± 3.8 0.90
SBP (mmHg) 135.0 ± 17.1 134.5 ± 17.2 137.4 ± 18.9 0.51
DBP (mmHg) 81.5 ± 9.5 80.9 ± 9.2  81.9 ± 9.8 0.78
PP (mmHg) 53.5 ± 14.4 53.7 ± 14.4 55.4 ± 14.8 0.57
Heart rate (beats/min) 72.7 ± 9.7 72.1 ± 9.9 72.1 ± 11.7 0.66
Height (m) 1.73 ± 0.07 1.74 ± 0.06 1.73 ± 0.06 0.15
Fasting glucose (mg/dL) 107.6 ± 26.7 112.4 ± 35.1 110 ± 35.1 0.34
Hematocrit 43.8 ± 3.1 44.1 ± 3.4 43.7 ± 2.9 0.58
Hemoglobin (g/dL) 15.1 ± 1.2 15.4 ± 1.2 15.2 ± 1.1 0.29
LDL (mg/dL) 112.9 ± 37.1 111.9 ± 39.6 109.1 ± 39.7 0.73
HDL(mg/dL) 49.4 ± 13.5 46.8 ± 11.2 46.1 ± 10.9 0.03
Total/HDL ratio  4.93 ± 1.43 5.1 ± 1.58 5.2 ± 1.45 0.23
Alcohol (g/day) 14.2 ± 18.5 14.2 ± 18 11.9±17.3 0.37
Smoking (pack-years) 20.0 ± 24.0 24.6 ± 28.6 23.3 ± 26.8  0.20
Calories (kcal) 1,995 ± 594 2,106 ± 626 1,975 ± 718 0.02
Calcium (mg) 780 ± 353 905 ± 443 768 ± 358 0.02
Potassium (mg) 3,255 ± 992 3,510 ± 465 3,389 ± 1379 0.14
Sodium (mg) 3,757 ± 1,579 3,951 ± 1,816 3,773 ± 1,878 0.69
Categorical variable [n (%)]
Education 0.16
Unfinished high school  43 (10.5) 15 (6.9) 9 (6.5)
High school 238 (58.2) 52 (72.2) 87 (63.0)
College and above 128 (31.3) 15 (20.8) 42 (30.4)
Family history of HTN  157 (38.4) 30 (41.7) 51 (36.9) 0.80
Hypertension 164 (40.1)  29 (40.3) 62 (44.9) 0.61
Ischemic heart diseases 59 (14.4) 15 (20.8) 28 (20.3) 0.16
Diabetes 18 (4.4) 6 (8.33) 15 (10.8) 0.02
Hypertension treatment  34 (8.3) 8 (11.1) 12 (8.7) 0.74
Hyperlipidemia treatment 48 (11.7) 6 (8.3) 17 (12.3) 0.66
Diabetes treatment 13 (3.2) 5 (6.9) 10 (7.3) 0.08
Bone lead levels [median (IQR)]
Tibia lead (µg/g) 18 (12–27) 20 (14–27) 19 (14–26) 0.31
Patella lead (µg/g) 26 (17–37) 25 (17–37) 27 (19–37) 0.94
Abbreviations: DBP, diastolic blood pressure; HTN, hypertension; IQR, interquartile range; LDL, low‑density lipoprotein; 
SBP, systolic blood pressure.Zhang et al.
1264  v o l u m e  118 | n u m b e r 9 | September 2010  •  Environmental Health Perspectives
levels in tibia (13 µg/g) and patella (19 µg/g) 
were associated with 3.3 mmHg [95% con-
fidence interval (CI), 0.16–6.46 mmHg) 
and 2.95 mmHg (95% CI, 0–5.92 mmHg) 
increases in PP, respectively]. Although bone 
lead levels were also associated with PP ele-
vation among C282 variant and wild-type 
subjects, those associations were small in mag-
nitude and not statistically significant.
In an adjusted plot of PP versus tibia lead 
stratified by the HFE genotype that was done 
using GAMM (Figure 1), we found that the 
estimated degrees of freedom for the penal-
ized splines of the tibia lead to predict PP in 
all three HFE genotype groups were 1, which 
suggests that there was no evidence of a non-
linear shape to the dose–response relationship 
between tibia lead levels and PP, with the 
steepest slope in H63D subjects and a more 
modest slope in C282Y variants compared 
with the wild-type subjects. Similar modifying 
effects were noted in the association of patella 
lead with PP (data not shown).
Because blood pressure and cholesterol 
level in blood could influence arterial stiff-
ness, one might be concerned that treatment 
for hypertension and hyperlipidemia could 
alter any effect modification by HFE variants. 
We examined this possibility by including a 
term for use of the related medications at the 
baseline in our study population in the multi-
variate models and also repeating the analyses 
after further excluding subjects who took the 
medications for those diseases. These models 
yielded similar results in the interaction of 
bone lead with H63D variant. Further adjust-
ment for diagnosis of diabetes and ischemic 
heart disease at the baseline did not change 
the results (data not shown). The same was 
also true for analysis-restricted Caucasians 
(data not shown).
Discussion
Although public health initiatives have been 
successful in decreasing environmental lead 
exposures in the United States and other 
industrialized nations, recent reports using 
data from the Third National Health and 
Nutrition Examination Survey (NHANES 
III) (Menke et al. 2006; Schober et al. 2006) 
as well as the NAS (Weisskopf et al. 2009) 
suggest that even low-level environmental 
lead exposure is associated with all-cause and 
cardio  vascular mortality. Moreover, genetic 
variations render some people especially 
susceptible to lead’s toxicity (Onalaja and 
Claudio 2000), and identifying such height-
ened susceptibility is important not only for a 
better understanding of the etiologic relation 
between lead and adverse cardiovascular out-
comes in older adulthood, but also for more 
accurately defining preventive and therapeutic 
measures. In the present longitudinal study 
of 619 older, community-dwelling men, we 
demonstrated a modifying influence of HFE 
genotype on the relation between cumulative 
lead burden and PP, after adjusting for poten-
tial confounders. We found that the linear 
relationship of PP with bone lead was par-
ticularly strong among H63D variant carriers 
compared with C282Y variant carriers and 
wild-type participants. That is, individuals 
carrying the H63D allele showed the strongest 
PP increases in relation to bone lead levels—
even though they also had somewhat lower 
bone lead levels overall. As we have recently 
demonstrated and discussed in our lead and 
gene interaction models of cognition and 
electrocardiographic conduction (Park et al. 
2009; Wang et al. 2007), the observed differ-
ence between the two HFE variants provides 
striking evidence of an allele-specific pre-
disposition to lead toxicity and suggests that 
individuals with H63D variants may have a 
significantly higher risk for lead-increased PP. 
Given that a 10-mmHg wider PP increases 
the risk of major cardio  vascular complications 
and mortality by nearly 20% (Blacher et al. 
2000), the apparent lead effects, if causal, 
could account for approximate 6.6% risk of 
cardiovascular disease. Moreover, the find-
ings from our present and previous studies 
underscore the importance of considering 
both genetic and environmental factors in 
the mechanisms involved in a multi  factorial 
condition such as increased arterial stiffness, 
rather than the typical approach of evaluating 
one component or the other.
The progression of PP with advancing age 
is largely attributed to progressive central arte-
rial stiffening as a consequence of altered vas-
cular structure and function with disruption 
of elastin, increased collagen, calcification, 
and atherosclerosis. Lead accumulation in 
the human aorta (Barry and Mossman 1970; 
Schroeder and Tipton 1968) may contribute 
to accelerating arterial degenerative processes 
by reducing availability of nitric oxide and 
promoting oxidative damage and vascular 
inflammation (Vaziri and Sica 2004), pur-
ported mechanisms of vascular aging (Touyz 
2004). It is possible that acceleration of PP 
may result from extra-osseous deposition 
of lead released from aged bone, and HFE 
genotypes affect PP elevation by modulating 
internal lead distribution between bone and a 
vulnerable arterial tree. However, the findings 
of a stronger association of PP with tibia lead 
than with patella lead (Perlstein et al. 2007) 
make this possibility somewhat less likely. 
The patella is composed mostly of trabecular 
bone, which has a higher reabsorption rate 
and is considered the major skeletal source 
of circulating lead (Hu 1998); thus, patella 
bone lead would have been expected to exert 
the greatest impact on PP if the mechanism 
of that impact required mobilization of bone 
lead stores. By contrast, the tibia is a cortical 
bone with a slow rate of bone turnover and a 
longer half-life with respect to lead levels. The 
stronger association of tibia lead with PP is 
consistent with bone lead as a proxy dosime-
ter for arterial lead accumulation and an effect 
of chronic lead exposure on vascular structure 
and function. Given the fact there was no sig-
nificant difference in bone lead levels by HFE 
genotypes in the present study, toxicokinetic 
modifications seems unlikely to account for 
the apparent H63D effects, although its role 
in transporting lead into the blood vessel wall 
is unknown.
Both polymorphisms are common in the 
U.S. population (Burke et al. 2000; Wright 
et al. 2004), and the prevalence estimates for 
Table 3. Adjusted parameter estimators in the difference of PP (mmHg) for an IQR increase in bone lead 
marker by HFE genotype.
Genotype Subjects (n) Total observations
Tibia lead IQR = 13 µg/g 
β (95% CI)
Patella lead IQR = 19 µg/g 
β (95% CI)
Wild types 409 755 0.38 (0–1.96) 0.26 (0–1.78)
H63D 138 256 3.30 (0.16–6.46) 2.95 (0–5.92)
C282Y 72 137 0.89 (0–5.24) 0.55 (0–1.66)
Any HFEa 210 393 2.90 (0.31–5.51) 2.83 (0.32–5.37)
All models were adjusted for baseline age; age squared; time elapsed from the baseline; height; education; alcohol 
intake; smoking; daily intakes of calcium, sodium, and potassium; calorie intake; physical activity; diabetes; family history 
of hypertension; heart rate; HDL; total cholesterol:HDL ratio; and waist circumference. 
aIncludes H63D and C282Y variants only.
Figure 1. Adjusted association between tibia lead 
levels and change in PP by HFE genotypes in 619 
community‑exposed men with a total of 1,148 
observations from the GAMM with interactions 
between HFE genotypes and tibia lead fit as penal‑
ized spline that allows the relation between the 
exposure and response to be more flexible and 
thus allows for possible nonlinearity of the asso‑
ciation. The covariates adjusted for are the same 
as in Table 3.
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HFE variants are 5.4–17% for C282Y and 
10–32% for H63D, respectively, which are 
similar to the prevalence rates in our study 
population. C282Y variants have been known 
to accumulate more iron in the body than 
H63 variants or wild-type subjects. Because 
the excess iron accumulation over physiologi-
cal need (iron overload) has been implicated 
in atherosclerosis (Sullivan 1981) and arterial 
stiffness (Cheung et al. 2002), the accelera-
tion of PP may be a central vascular outcome 
of synergistic interaction between lead and 
altered iron metabolism or endoplasmic reticu-
lum stress in HFE variants. As such, one might 
have expected a greater PP elevation per unit 
increase in body lead burden among C282Y 
variants compared with H63D variants. 
However, the current data suggest quite the 
opposite, indicating that H63D variant aug-
ments the vascular toxicity of lead and appears 
to be independent of iron load pathway.
Findings from in vitro studies of 
human neuronal cells demonstrate an HFE 
gene pleiotropic effect: The H63D variant 
enhances, whereas C282Y decreases, oxidative 
stress and production of monocyte chemo-
attractant protein-1 (MCP-1) (Lee et al. 
2007; Mitchell et al. 2009). More interest-
ingly, H63D associations with MCP-1 were 
also observed in patients with hemochroma-
tosis in vivo (Lawless et al. 2007). MCP-1 is 
a potent chemokine secreted by vascular or 
circulating cells and plays an important role 
in the regulation of leukocyte trafficking. It 
has been proposed that the pathogenesis of 
atherosclerosis is associated with an inflamma-
tory response characterized in part by exces-
sive recruitment of leukocytes from blood 
stream into the vessel wall (Braunersreuther 
et al. 2007). The relationships between 
H63D and MCP-1 and oxidative stress sug-
gest another mechanism: that the modified 
association of H63D mutation with lead may 
be related to increased MCP-1–mediated 
inflammatory responses. Although the under-
lying mechanism(s) is not clear, the common 
prooxidant and proinflammatory tendencies 
shared by lead and the H63D genotype would 
clearly be consistent with biologic plausibil-
ity: the putative interaction between lead and 
H63D variant enhances vascular damage and 
inflammatory responses and, consequently, 
accelerates atherosclerosis and PP progress. 
Because we were not able to assess body redox 
status and MCP-1 and other inflammatory 
mediators in the blood, we cannot test this 
hypothesis in the statistical analysis.
It is noteworthy that two population stud-
ies, the Hemochromatosis and Iron Overload 
Screening and the Atherosclerosis Risk in 
Communities, reported that C282Y homo-
zygosity was associated with lower total and 
low-density lipoprotein (LDL) cholesterol lev-
els (Adams et al. 2009; Pankow et al. 2008). 
The failure of the C282Y variants to modify 
the relationship between lead and PP may be, 
in fact, the results of the perturbation of the 
body lipid metabolism in C282Y variants that 
may thus protect against arterial stiffening. 
The precipitation of LDL onto the arterial 
wall is the first key step to initiate vascular 
inflammatory responses and the development 
of fatty streaks and atherosclerotic plaques. 
Thus, lower LDL reduces arterial wall inflam-
mation and should be associated with lower 
blood vessel stiffness. In our analysis, the LDL 
levels in C282Y and H63D variant carriers 
appeared to be lower than those in HFE wild 
types, but this was not statistically significant 
(Table 2). Thus, it is unlikely that this can 
explain the current finding.
Regardless of the actual mechanism, this 
study suggests a molecular link between accel-
erated PP and lead exposure and raises the 
possibility that H63D mutation is a previ-
ously unrecognized genetic risk factor for 
accelerated arterial aging. Because the pro-
gressive increase in arterial stiffness, marked 
by increased PP, is the common pathway 
of multiple risk factors that lead to similar 
cardiovascular diseases [e.g., left ventricular 
hypertrophy, myocardial infarction, and con-
gestive heart failure (Zieman et al. 2005)], the 
modified associations between community 
exposure to lead and PP by common genetic 
variant, H63D, is compelling and has public 
health relevance. Since the discovery of the 
HFE gene more than a decade ago (Feder 
et al. 1998), its role in cardiovascular diseases 
has been studied intensively but has yielded 
conflicting results. Our study, in conjunc-
tion with the known high prevalence and low 
penetrance of the HFE gene, strongly sug-
gests that discrepancies across studies may 
reflect that HFE polymorphisms may not 
independently predict such pathology, but 
may instead enhance the influence of environ-
mental factors, such as lead, on the develop-
ment of cardiovascular diseases in individuals 
who carry HFE mutations. Moreover, because 
both lead and H63D have been linked to 
Alzheimer’s disease (Berlin et al. 2004; Zawia 
et al. 2009), amyotrophic lateral sclerosis 
(Kamel et al. 2002; Sutedja et al. 2007), and 
male infertility (Benoff et al. 2000; Gunel-
Ozcan et al. 2009), our work underscores the 
need for examination of the interaction of 
H63D mutation and lead exposure as a poten-
tial mechanism of other chronic diseases.
The strengths of this study include con-
siderable follow-up that has enabled us to 
minimize the potential for biases that are 
often encountered in cross-sectional or case–
control studies and to establish more clearly 
the temporal nature of the association. The 
NAS cohort was established about 35 years 
before the discovery of HFE; thus, partici-
pants had not been previously screened for 
mutations or selected based on knowledge of 
their genotype. 
Our study has several limitations. Because 
the NAS study was conducted almost exclu-
sively in white men, the conclusion from our 
study may be not applicable to women and 
nonwhite people. As in any study of genetic 
association, population substructure might 
produce the observed interaction; however, 
the present study population is very homo-
geneous, with 95% being of European descent. 
We cannot rule out residual or unmeasured 
time-dependent and time-independent con-
founding factors and interactions with other 
genetic polymorphisms or environmental fac-
tors. Other considerations include the limited 
number of C282Y or H63D homozygotes, 
possible HFE gene disequilibrium with other 
measured covariates and limited information 
on clinical diagnosis of hemochromatosis, and 
markers of inflammation (MCP-1) or iron 
metabolism (serum ferritin and transferrin 
saturation levels). The HFE gene is located on 
chromosome 6 (6p21.3) (Feder et al. 1998). 
We cannot exclude a possibility that the 
apparent effect modification may be caused 
by gene(s) in proximity to the HFE gene in 
chromosome 6 that influence or regulate PP 
or resulted from effects of less-common HFE 
variants, such as S65C (Pedersen and Milman 
2009). Although possible, we think that those 
two possibilities are very unlikely. In either 
case, the impact should be seen in all sub-
jects and not limited to H63D subjects as 
seen in our study. We did several sensitivity 
analyses by further controlling for diagnoses 
of hypertension and diabetes and treatments 
of hypertension and hyperlipidemia collected 
at baseline. Because of incomplete follow-up 
information on these variables in the data set 
that we examined in the present study, such 
sensitivity analyses may not completely rule 
out the possible confounding effect of diabe-
tes, hypertension, or use of antihypertensive 
and lipid-lowering drugs.
In conclusion, our study of 619 older, 
community-dwelling men provides the first 
evidence that the H63D mutation signifi-
cantly modifies the association between bone 
lead and PP. These observations support the 
notion of combined influences of genetic sus-
ceptibility and environmental lead exposure 
on the development of arterial stiffness.
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